02/07/2012 07:35:00

Glaxo, Theravance Get Positive Results From LAMA/LABA (UMEC/VI) in COPD

Related content
09 Jan - 
Adaptimmune confirms GSK Nomination of Second Adaptimmu..
05 Dec - 
Adaptimmune Announces Initiation of Myxoid/Round Cell L..

LONDON--GlaxoSmithKline PLC (GSK.LN) and Theravance, Inc. (THRX) Monday announced positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD

MAIN FACTS:

-The results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease.

-These four studies include two 24-week efficacy studies that compared the combination LAMA/LABA, its components and placebo and two 24-week active comparator studies that compared the combination with the LAMA tiotropium, a widely prescribed maintenance bronchodilator for COPD.

-LAMA/LABA is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, administered by a new dry powder inhaler.

-UMEC/VI is a once-daily investigational medicine currently under development for the maintenance treatment of COPD.

-Write to Razak Musah Baba at razak.baba@dowjones.com

(END) Dow Jones Newswires

July 02, 2012 02:35 ET (06:35 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Form 8.5 (EPT/RI) - E2V Technologies plc

07/02/2017 07:47:25
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY ..

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

06/02/2017 15:31:59
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECU..

Alliance Trust PLC : Transaction in Own Shares

06/02/2017 07:00:03
6 February 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 3 February 2017 the Comp..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
JACC: Clinical Electrophysiology Manuscript Featuring BioSig's PURE EP System in Top Five Most Influential of 2016
2
JACC: Clinical Electrophysiology Manuscript Featuring BioSig’s PURE EP System in Top Five Most Influential of 2016
3
BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2016
4
Impinj and STANLEY Healthcare Announce Partnership and Platform Integration
5
Thinfilm Completes Purchase of EAS Manufacturing Equipment for Roll-to-Roll Line

Related stock quotes

Glaxosmithkline PLC ORD .. 1,635.00 -0.3% Stock price decreasing
GlaxoSmithKline PLC 41.34 1.0% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 February 2017 15:30:56
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170217.2 - EUROWEB7 - 2017-02-20 16:30:56 - 2017-02-20 15:30:56 - 1000 - Website: OKAY